Report copyright - PHASE 2/3 TRIAL OF SUBCUTANEOUSLY ADMINISTERED … · 2018. 12. 1. · phase 2/3 trial of subcutaneously administered marzeptacog alfa (activated) an engineered fviia in hemophilia
Please pass captcha verification before submit form
Please pass captcha verification before submit form